Sound Pharma Gets $2.1M Contract

Luke Timmerman8/19/09

Sound Pharmaceuticals, the Seattle-based developer of treatments for hearing loss, said today it has received a $2.1 million contract from the Office of Naval Research, through its Science and Technology Division. The award will be used to expand ongoing development of the company’s lead drug, SPI-1005, for new types of hearing loss, and it will allow the company to identify new protein targets that could help expand its pipeline, said CEO Jonathan Kil. This is the third grant the company has received from the Naval research office since 2005.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.